Investments
14Portfolio Exits
2Funds
2
Want to inform investors similar to Brain Trust Accelerator Fund about your company?
Submit your Analyst Briefing to get in front of investors, customers, and partners on CB Insights’ platform.
Latest Brain Trust Accelerator Fund News
Sep 23, 2020
Investment will allow NeuroTherapia to develop orally-available treatment for neurodegenerative disease. CLEVELAND, September 22, 2020-- NeuroTherapia, Inc., a clinical-stage company focused on developing therapies for neurodegenerative diseases, announced today the closing of its Series A financing of $8.8M. The Series A round, led by Brain Trust Accelerator Fund II, included investments from The Cleveland Clinic Foundation, Dolby Family Ventures and Alzheimer's Drug Discovery Foundation. NeuroTherapia is developing an orally available cannabinoid receptor agonist, NTRX-07, for the treatment of neuroinflammation, which likely plays a critical role in the progression of neurodegenerative diseases. "We were particularly attracted to this novel strategy for inhibiting neuroinflammation," commented John Reher, managing director of Brain Trust and lead investor in this financing. "We believe that inhibiting neuroinflammation may be beneficial not only for treating neurodegenerative diseases but could also be an important strategy for treating other brain disorders such as glioblastoma." Coincident with the financing, the company welcomes Karoly Nikolich, Ph.D. to its Board of Directors. Dr. Nikolich is an experienced scientist and entrepreneur, co-founding a number of biotech companies, and currently serving as CEO of Alkahest. He also led Genentech's entry into neuroscience and served as a venture partner with Pivotal BioVenture Partners. Dr. Nikolich joins Mr. Reher, who will serve as Chairman of the Board, Tony Giordano, Ph.D., NeuroTherapia's President and CEO, and Akhil Saklecha, M.D., from Cleveland Clinic on the Board. NeuroTherapia is currently completing its first-in-human clinical trial using NTRX-07 with funding provided in part by a grant from the Alzheimer's Association. The company will use the Series A funds to finish this work while also undertaking a number of preclinical studies. The additional studies are designed to support subsequent clinical trials in subjects with neurodegeneration to show safety following longer-term administration, as well as to demonstrate biological activity. "We are extremely fortunate to have this tremendous group of venture capitalists working with us," said Dr. Giordano. "Their expertise in developing molecules for brain disorders is greatly appreciated and I look forward to working with them in advancing NTRX-07 and our emerging pipeline of products." NeuroTherapia also recently received a $150,000 Technology Validation and Start-up Fund grant from the Ohio Third Frontier program of the Ohio Development Services Agency, which will allow the Company to complete additional research on the biodistribution of NTRX-07 following radiolabeling of the molecule. About NeuroTherapia NeuroTherapia, Inc. is a Cleveland-based biotech company developing a novel small molecule, NTRX-07, for the treatment of neurodegenerative disorders. NTRX-07 is a small orally-available molecule that targets receptors that are known to be increased in diseases including Alzheimer's disease (AD), ALS, MS and chronic pain syndromes. In various animal models of AD, NTRX-07 restored normal function of the microglia (key immune cells in the brain), which in turn decreased microglial-induced inflammation, reduced levels of the Alzheimer's associated Ab peptide in the brain, and substantially improved neuronal synaptic plasticity, learning, and memory. Additional information about NeuroTherapia can be found at www.neurotherapia.com.
Brain Trust Accelerator Fund Investments
14 Investments
Brain Trust Accelerator Fund has made 14 investments. Their latest investment was in Thirteen Lune as part of their Seed VC - II on January 1, 2023.

Brain Trust Accelerator Fund Investments Activity

Date | Round | Company | Amount | New? | Co-Investors | Sources |
---|---|---|---|---|---|---|
1/19/2023 | Seed VC - II | Thirteen Lune | $8M | Yes | Brain Trust Accelerator Fund, and Undisclosed Investors | 1 |
9/22/2020 | Series A | NeuroTherapia | $8.8M | Yes | 4 | |
8/28/2018 | Series A - II | Chase Therapeutics | $4M | No | 1 | |
11/22/2017 | Series A | |||||
3/1/2015 | Seed VC - II |
Date | 1/19/2023 | 9/22/2020 | 8/28/2018 | 11/22/2017 | 3/1/2015 |
---|---|---|---|---|---|
Round | Seed VC - II | Series A | Series A - II | Series A | Seed VC - II |
Company | Thirteen Lune | NeuroTherapia | Chase Therapeutics | ||
Amount | $8M | $8.8M | $4M | ||
New? | Yes | Yes | No | ||
Co-Investors | Brain Trust Accelerator Fund, and Undisclosed Investors | ||||
Sources | 1 | 4 | 1 |
Brain Trust Accelerator Fund Portfolio Exits
2 Portfolio Exits
Brain Trust Accelerator Fund has 2 portfolio exits. Their latest portfolio exit was Chase Pharmaceuticals on November 22, 2016.
Date | Exit | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Acquirer | Sources |
---|---|---|---|---|---|
11/22/2016 | Acquired | 4 | |||
Date | 11/22/2016 | |
---|---|---|
Exit | Acquired | |
Companies | ||
Valuation | ||
Acquirer | ||
Sources | 4 |
Brain Trust Accelerator Fund Acquisitions
1 Acquisition
Brain Trust Accelerator Fund acquired 1 company. Their latest acquisition was Blue Buddha Beverages on December 23, 2014.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
---|---|---|---|---|---|---|
12/23/2014 | Acquired | 1 |
Date | 12/23/2014 |
---|---|
Investment Stage | |
Companies | |
Valuation | |
Total Funding | |
Note | Acquired |
Sources | 1 |
Brain Trust Accelerator Fund Fund History
2 Fund Histories
Brain Trust Accelerator Fund has 2 funds, including Brain Trust Accelerator Fund II.
Closing Date | Fund | Fund Type | Status | Amount | Sources |
---|---|---|---|---|---|
4/4/2017 | Brain Trust Accelerator Fund II | Early-Stage Venture Capital | Open | $12.03M | 2 |
12/31/2006 | Brain Trust Accelerator Fund LP |
Closing Date | 4/4/2017 | 12/31/2006 |
---|---|---|
Fund | Brain Trust Accelerator Fund II | Brain Trust Accelerator Fund LP |
Fund Type | Early-Stage Venture Capital | |
Status | Open | |
Amount | $12.03M | |
Sources | 2 |
Brain Trust Accelerator Fund Team
1 Team Member
Brain Trust Accelerator Fund has 1 team member, including current Managing Director, John M. Reher.
Name | Work History | Title | Status |
---|---|---|---|
John M. Reher | Managing Director | Current |
Name | John M. Reher |
---|---|
Work History | |
Title | Managing Director |
Status | Current |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.